title: K+ channels as potential targets for the treatment of gastrointestinal motor disorders.
abstract: K(+) channels play important functional roles in excitable cells, as neurons and muscle cells. The activation or inhibition of K(+) channels hyperpolarizes or depolarizes the cell membrane, respectively. These effects determine in the smooth muscle decrease or increase in Ca(2+) influx through voltage-gated Ca(2+) (CaV1.2) channels and relaxation or contraction, respectively. Recent studies highlight the importance of voltage-dependent type 7 K(+) (KV7 or KCNQ) channels in regulating muscle tone and contractility in stomach and colon. KV7 channels, that include 5 subtypes (KV7.1-7.5), are activated at relatively negative potential values, close to those of the resting membrane potential for the smooth muscle cells of some segments of the gastrointestinal tract. Thus, they contribute to set the resting membrane potential and their blockade induces increase in smooth muscle contractility in stomach and colon. In addition, KV7 channel activation produces profound relaxations of gastric and colonic smooth muscle. Therefore, KV7 channel activators could be used to relax the smooth muscle and relieve symptoms in diseases such as functional dyspepsia and irritable bowel syndrome with prevalent diarrhea. The discovery of activators selective for the channel subtypes present in the smooth muscle, mainly KV7.4 and 7.5, would allow avoiding adverse cardiac and nervous system effects. A further step forward would be characterizing putative differences among the KV7 channel subtypes expressed in the various smooth muscles and synthesizing molecules specific for the gastrointestinal smooth muscle.
authors.affiliation: Institute of Pharmacology, School of Medicine, Catholic University of the Sacred Heart, L.go F. Vito 1, 00168 Rome, Italy. Electronic address: dcurro@rm.unicatt.it.
authors.forename: Diego
authors.initials: D
authors.lastname: Currò
mesh_terms: D000818:Animals; D004415:Dyspepsia / Q000188:drug therapy* / Q000378:metabolism; D005769:Gastrointestinal Motility / Q000187:drug effects*; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000378:metabolism; D051656:KCNQ Potassium Channels / Q000378:metabolism*; D008564:Membrane Potentials / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects
chemical_list: D051656:KCNQ Potassium Channels
keywords: 4-Aminopyridine (PubChem CID: 1727); Apamin (PubChem CID: 16218850); DMP-543 (PubChem CID: 9887884); E-4031 (PubChem CID: 3185); Flupirtine; Flupirtine (PubChem CID: 53276); Iberiotoxin (PubChem CID: 16132435); K(V)7 channels; KCNQ channels; Linopirdine (PubChem CID: 3932); Retigabine; Retigabine (PubChem CID: 121892); Tetraethylammonium (PubChem CID: 5413); XE-991 (PubChem CID: 656732)